JFS Wealth Advisors’s Kezar Life Sciences KZR Stock Holding History

JFS Wealth Advisors’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50	Closed	-$4K	–	1975
2022 Q3	$4K	Hold	50	–	–	﹤0.01%	1079
2022 Q2	$4K	Buy	+50	New	+$4.41K	﹤0.01%	1090

Other funds holding KZR

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

JFS Wealth Advisors's KZR Position: Q4 2022 in Review

JFS Wealth Advisors sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 50 shares — an estimated $4K sold.

JFS Wealth Advisors first reported a position in KZR in Q2 2022 and held it in 2 quarters. The position peaked at $4K in Q3 2022. 123 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

JFS Wealth Advisors reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
JFS Wealth Advisors sold 50 Kezar Life Sciences shares in Q4 2022, an estimated $4K.
JFS Wealth Advisors first reported a position in Kezar Life Sciences in Q2 2022 and held it in 2 quarters.
JFS Wealth Advisors's Kezar Life Sciences position peaked at $4K in Q3 2022.
123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on JFS Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.